High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
J. Clin. Invest. David-Alexandre Gross, et al. 113:425 doi:10.1172/JCI19418 [Go to this article.]

Figure 3
In vivo antitumor immunity induced in HHD mice vaccinated against mTERT high- and low-affinity epitopes. HHD mice were vaccinated with high-affinity or heteroclitical P1Y peptides once and then again 2 weeks later. Mice were challenged 7–10 days after the second vaccination with 2 × 10⁴ EL4/HHD cells. The antitumor immunity was evaluated by measuring the tumor size 35–40 days after challenge (a) and survival (b). Cumulative results from three independent experiments are shown. Tumor sizes in HHD mice vaccinated with p988Y and p572Y were statistically different from the tumor sizes in control HHD mice (P < 0.0001), as assessed by nonparametric Mann-Whitney U test analysis (*). Survival statistically different from that of control gp100₁₅₄-vaccinated HHD mice is indicated; **P < 0.03 by Tarone and Ware test.